These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 30012209)

  • 1. Sick sinus syndrome associated with anti-programmed cell death-1.
    Hsu CY; Su YW; Chen SC
    J Immunother Cancer; 2018 Jul; 6(1):72. PubMed ID: 30012209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.
    Choi B; McBride A; Scott AJ
    Am J Health Syst Pharm; 2019 Oct; 76(21):1749-1752. PubMed ID: 31612928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
    Thomas S; Bae C; Joy-Ann T; Traverse W
    J Oncol Pharm Pract; 2020 Jun; 26(4):995-999. PubMed ID: 31575354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab.
    Acero Brand FZ; Suter N; Adam JP; Faulques B; Maietta A; Soulières D; Blais N
    J Immunother Cancer; 2018 Mar; 6(1):22. PubMed ID: 29548299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L; Zou X; Chen Y; Bai X; Liang T
    Front Immunol; 2020; 11():2076. PubMed ID: 32973816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
    Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
    Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer: A case report.
    Wu Z; Lai L; Li M; Zhang L; Zhang W
    Medicine (Baltimore); 2017 Dec; 96(51):e9431. PubMed ID: 29390572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring.
    Katsume Y; Isawa T; Toi Y; Fukuda R; Kondo Y; Sugawara S; Ootomo T
    Intern Med; 2018 Nov; 57(21):3157-3162. PubMed ID: 29877257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sinus Node Dysfunction Co-occurring with Immune Checkpoint Inhibitor-associated Myocarditis.
    Nishikawa T; Kunimasa K; Ohta-Ogo K; Ikeda Y; Yasui T; Shioyama W; Oka T; Honma K; Hatakeyama K; Kumagai T; Fujita M
    Intern Med; 2022 Jul; 61(14):2161-2165. PubMed ID: 35283377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three cases of immune-related hypopituitarism after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
    Furuichi N; Naganuma A; Kaburagi T; Suzuki Y; Hoshino T; Shibusawa N; Horiguchi S; Hatanaka T; Kakizaki S; Uraoka T
    Clin J Gastroenterol; 2023 Jun; 16(3):422-431. PubMed ID: 36821067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K; McGettigan S; Elenitsas R; Chu EY
    J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy.
    Quach HT; Robbins CJ; Balko JM; Chiu CY; Miller S; Wilson MR; Nelson GE; Johnson DB
    Oncologist; 2019 Jul; 24(7):872-876. PubMed ID: 30936376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case of pembrolizumab-induced myocarditis presenting as torsades de pointes with safe re-challenge.
    Lee DH; Armanious M; Huang J; Jeong D; Druta M; Fradley MG
    J Oncol Pharm Pract; 2020 Sep; 26(6):1544-1548. PubMed ID: 32089073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.
    Zhang J; Zhang P; Xu QY; Zhu YT; Chen W; Ji C
    Australas J Dermatol; 2022 Feb; 63(1):e71-e74. PubMed ID: 34463968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy.
    Esfahani K; Buhlaiga N; Thébault P; Lapointe R; Johnson NA; Miller WH
    N Engl J Med; 2019 Jun; 380(24):2375-2376. PubMed ID: 31189042
    [No Abstract]   [Full Text] [Related]  

  • 16. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review.
    Johansen A; Christensen SJ; Scheie D; Højgaard JLS; Kondziella D
    Neurology; 2019 Apr; 92(14):663-674. PubMed ID: 30850443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drugs and new toxicities: pembrolizumab-induced myocarditis.
    Inayat F; Masab M; Gupta S; Ullah W
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29367376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature.
    Gunjur A; Klein O; Kee D; Cebon J
    J Immunother Cancer; 2019 Sep; 7(1):241. PubMed ID: 31488221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
    Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
    J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.